Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)
Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .
Latest Key Developments inPharmaceuticals
- Indian Pharma Firms Sent Notices By Govt Body For Introducing Drugs Without Approval
- Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa For The Maintenance Treatment Of Adults With Acromegaly
- Eckert & Ziegler Increases Profit Forecast To 4 Eur Per Share
- Jacobson Pharma Corporation Announces Acquisition Of 43% Stake In Orizen Capital